HUP0401441A2 - Az 5-CNAC mint mellékpajzsmirigy hormon fragmentumok orális hordozószere - Google Patents

Az 5-CNAC mint mellékpajzsmirigy hormon fragmentumok orális hordozószere

Info

Publication number
HUP0401441A2
HUP0401441A2 HU0401441A HUP0401441A HUP0401441A2 HU P0401441 A2 HUP0401441 A2 HU P0401441A2 HU 0401441 A HU0401441 A HU 0401441A HU P0401441 A HUP0401441 A HU P0401441A HU P0401441 A2 HUP0401441 A2 HU P0401441A2
Authority
HU
Hungary
Prior art keywords
pth
cnac
parathyroid hormone
fragments
oral administration
Prior art date
Application number
HU0401441A
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0401441A2 publication Critical patent/HUP0401441A2/hu
Publication of HUP0401441A3 publication Critical patent/HUP0401441A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány mellékpajzsmirigy-hormon (PTH) orális adagolásáravonatkozik, közelebbről olyan PTH-fragmentumok adagolására, amelyek epeptidhormonok legalább az első 28 N-terminális[PTH (1-28)] éslegfeljebb az első 41 N-terminális aminosavcsoportját[PTH-(1-41)]tartalmazzák. A találmány értelmében e peptidhormon fragmentumokatolyan orális adagolású gyógyszer-kompozíciókban adják be, amelyek N-(5-klór-szaliciloil)-8-amino-kaprilsavat (5-CNAC) vagy ennek sójátvagy a só hidrátját tartalmazzák hordozóvegyületként. E kompozíciókelsősorban új csont képződésének serkentésére, valamint csontritkuláskezelésére vagy megelőzésére használhatók. A találmány tárgyát képezika PTH hatékony orális adagolására szolgáló gyógyszerkompozíciók,valamint azok adagolási eljárása. Ó
HU0401441A 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments HUP0401441A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (2)

Publication Number Publication Date
HUP0401441A2 true HUP0401441A2 (hu) 2004-12-28
HUP0401441A3 HUP0401441A3 (en) 2012-09-28

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401441A HUP0401441A3 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Country Status (26)

Country Link
US (4) US20040242478A1 (hu)
EP (1) EP1420827B8 (hu)
JP (2) JP4959917B2 (hu)
KR (1) KR20040030120A (hu)
CN (1) CN1279981C (hu)
AT (1) ATE443527T1 (hu)
AU (1) AU2002333443C1 (hu)
BR (1) BRPI0211932B1 (hu)
CA (1) CA2453646C (hu)
CO (1) CO5560586A2 (hu)
CY (1) CY1109661T1 (hu)
DE (1) DE60233803D1 (hu)
DK (1) DK1420827T3 (hu)
EC (1) ECSP044961A (hu)
ES (1) ES2333587T3 (hu)
HU (1) HUP0401441A3 (hu)
IL (2) IL159714A0 (hu)
MX (1) MXPA04001418A (hu)
NO (1) NO328069B1 (hu)
NZ (1) NZ531018A (hu)
PL (1) PL210258B1 (hu)
PT (1) PT1420827E (hu)
RU (1) RU2322256C2 (hu)
SI (1) SI1420827T1 (hu)
WO (1) WO2003015822A1 (hu)
ZA (1) ZA200400242B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002344371B2 (en) * 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
RU2322256C2 (ru) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AU2004262906B2 (en) 2003-07-23 2008-04-03 Nordic Bioscience A/S Use of calcitonin in osteoarthritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
CA2607901C (en) * 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN103356997A (zh) * 2006-08-31 2013-10-23 诺瓦提斯公司 用于口服递送的包含hgh 的药物组合物
WO2008109385A2 (en) * 2007-03-02 2008-09-12 Novartis Ag Oral administration of a calcitonin
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
EP3256114A4 (en) * 2015-02-09 2018-11-21 Entera Bio Ltd. Treatment of osteoporosis
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
NZ257212A (en) * 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
EP1093819B1 (en) * 1997-02-07 2006-05-03 Emisphere Technologies, Inc. Compound and composition for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU1918300A (en) * 1998-11-25 2000-06-13 General Hospital Corporation, The Amino-terminal modified parathyroid hormone (pth) analogs
JP4588221B2 (ja) * 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
CA2402719C (en) * 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
AU2002344371B2 (en) * 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
RU2322256C2 (ru) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
CA2529604C (en) * 2003-07-11 2012-05-08 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
WO2003015822A1 (en) 2003-02-27
JP2005501852A (ja) 2005-01-20
SI1420827T1 (sl) 2010-01-29
AU2002333443C1 (en) 2009-10-08
KR20040030120A (ko) 2004-04-08
AU2002333443B2 (en) 2006-06-29
PT1420827E (pt) 2009-12-15
BR0211932A (pt) 2004-10-26
JP4959917B2 (ja) 2012-06-27
NZ531018A (en) 2006-03-31
NO328069B1 (no) 2009-11-23
EP1420827B8 (en) 2009-12-23
US20060217313A1 (en) 2006-09-28
PL365388A1 (en) 2005-01-10
MXPA04001418A (es) 2004-05-27
US20090264367A1 (en) 2009-10-22
CA2453646A1 (en) 2003-02-27
IL159714A (en) 2010-12-30
RU2322256C2 (ru) 2008-04-20
ZA200400242B (en) 2004-11-18
IL159714A0 (en) 2004-06-20
PL210258B1 (pl) 2011-12-30
CO5560586A2 (es) 2005-09-30
HUP0401441A3 (en) 2012-09-28
EP1420827B1 (en) 2009-09-23
BRPI0211932B1 (pt) 2016-12-06
CN1279981C (zh) 2006-10-18
CN1543357A (zh) 2004-11-03
CY1109661T1 (el) 2014-08-13
US20120088725A1 (en) 2012-04-12
US20040242478A1 (en) 2004-12-02
NO20040598L (no) 2004-02-10
DE60233803D1 (de) 2009-11-05
DK1420827T3 (da) 2009-12-21
JP2009242410A (ja) 2009-10-22
ES2333587T3 (es) 2010-02-24
ECSP044961A (es) 2004-03-23
ATE443527T1 (de) 2009-10-15
CA2453646C (en) 2008-09-30
RU2004107899A (ru) 2005-05-10
EP1420827A1 (en) 2004-05-26
US9272040B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
HUP0401441A2 (hu) Az 5-CNAC mint mellékpajzsmirigy hormon fragmentumok orális hordozószere
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
RU2000109305A (ru) ЗАЖИВЛЕНИЕ ПЕРЕЛОМОВ С ПОМОЩЬЮ АНАЛОГОВ ПЕПТИДА, ПОДОБНОГО ПАРАТИРЕОИДНОМУ ГОРМОНУ (РТНrР)
JP2002509854A5 (hu)
DE60017888D1 (de) Dinatrium-salze, monohydrate und ethanol-solvate
MXPA05002991A (es) Analogos de ghrh.
JP2004521123A5 (hu)
RU2013150659A (ru) Пероральное введение кальцитонина
ATE377026T1 (de) Behandlung von fettleibigkeit
CA2446929C (en) Orally administering parathyroid hormone and calcitonin
AU2002333443A1 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments
HU9503593D0 (en) Factor vii-derived peptides
WO2005004899A3 (de) Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen
PL372492A1 (en) Muteins of placental growth factor type 1, preparation method and application thereof
TH50339B (th) การสมานรอยหักของกระดูกโดยใช้อานาลอกของ PTHrP

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished